SCHEMBL6296647

SCHEMBL6296647

CCOC(=O)C1=C(C(F)(F)F)Nc2n[nH]cc2C1c1ccccc1OC

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.49
HTT P42858 3/20 0.49
DHFR P00374 3/20 0.48
ALDH1A1 P00352 4/20 0.45
ACHE P22303 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 1/20 0.42
CACNA1C Q13936 1/20 0.41
POLB P06746 1/20 0.40
HSP90AA1 P07900 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293656 0.88 CACNA1C (0.52) ACHECACNA1C
SCHEMBL6297236 0.88 MEN1 (0.44) GAAHTTALDH1A1ACHEMEN1
SCHEMBL6296650 0.86 ACHE (0.58) GAAHTTDHFRALDH1A1ACHE
SCHEMBL6292278 0.85 ADORA3 (0.47) GAADHFRALDH1A1ACHESMN1; SMN2
SCHEMBL6296612 0.85 MAPT (0.48) GAAHTTACHEMEN1KMT2A
SCHEMBL6293558 0.85 DHFR (0.48) HTTDHFRALDH1A1ACHESMN1; SMN2
SCHEMBL6292394 0.83 DHFR (0.47) HTTDHFRALDH1A1ACHEKDM4E
SCHEMBL6293595 0.83 HSD17B10 (0.50) GAAHTTDHFRALDH1A1ACHE
SCHEMBL6297295 0.83 ALDH1A1 (0.54) GAAHTTALDH1A1ACHESMN1; SMN2
Fumaric Acid SCHEMBL6296546 0.82 TSHR (0.42) GAAALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB GAA 229/4885HTT 2252/4885DHFR 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.